Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024
Biodesix (Nasdaq: BDSX), a leading diagnostic solutions company, has announced it will release its second quarter 2024 financial results on August 7, 2024, after the market closes. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a general business update. Interested parties can register for the webcast online, and analysts wishing to participate in the Q&A session should use a separate link. A replay of the webcast will be available on Biodesix's investor website approximately two hours after the call concludes. Participants are advised to join 15 minutes before the start time.
Biodesix (Nasdaq: BDSX), un'azienda leader nelle soluzioni diagnostiche, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 il 7 agosto 2024, dopo la chiusura del mercato. L'azienda organizzerà una conferenza telefonica e una trasmissione in streaming alle 4:30 p.m. Eastern Time nello stesso giorno per discutere i risultati e fornire un aggiornamento generale sull'attività. Le parti interessate possono registrarsi per la trasmissione online e gli analisti che desiderano partecipare alla sessione di domande e risposte devono utilizzare un link separato. Una registrazione della trasmissione sarà disponibile sul sito web per investitori di Biodesix circa due ore dopo la conclusione della chiamata. Si consiglia ai partecipanti di collegarsi 15 minuti prima dell'orario di inizio.
Biodesix (Nasdaq: BDSX), una empresa líder en soluciones diagnósticas, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el 7 de agosto de 2024, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica y una transmisión por webcast a las 4:30 p.m. hora del Este el mismo día para discutir los resultados y proporcionar una actualización general del negocio. Las partes interesadas pueden registrarse para el webcast en línea, y los analistas que deseen participar en la sesión de preguntas y respuestas deben utilizar un enlace separado. Una repetición del webcast estará disponible en el sitio web de inversores de Biodesix aproximadamente dos horas después de que concluya la llamada. Se aconseja a los participantes unirse 15 minutos antes de la hora de inicio.
Biodesix (Nasdaq: BDSX)는 진단 솔루션 분야의 선도적인 기업으로, 2024년 2분기 재무 결과를 2024년 8월 7일 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 오후 4시 30분에 결과를 논의하고 일반 비즈니스 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 개최할 예정입니다. 관심 있는 분들은 온라인에서 웹캐스트에 등록할 수 있으며, 질의응답 세션에 참여하고자 하는 분석가는 별도의 링크를 사용해야 합니다. 웹캐스트의 재방송은 전화 통화가 종료된 약 두 시간 후에 Biodesix의 투자자 웹사이트에서 이용할 수 있습니다. 참가자는 시작 15분 전에 로그인하는 것이 좋습니다.
Biodesix (Nasdaq: BDSX), une entreprise leader dans les solutions de diagnostic, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le 7 août 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique et un webinaire à 16h30, heure de l'Est le même jour pour discuter des résultats et fournir une mise à jour générale sur l'activité. Les parties intéressées peuvent s'inscrire en ligne pour le webinaire, et les analystes souhaitant participer à la session de questions-réponses doivent utiliser un lien séparé. Un enregistrement du webinaire sera disponible sur le site des investisseurs de Biodesix environ deux heures après la fin de l'appel. Les participants sont conseillés de se connecter 15 minutes avant l'heure de début.
Biodesix (Nasdaq: BDSX), ein führendes Unternehmen für diagnostische Lösungen, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am 7. August 2024 nach Marktschluss veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten, um die Ergebnisse zu besprechen und ein allgemeines Update zum Unternehmen zu geben. Interessierte Parteien können sich online für den Webcast registrieren, und Analysten, die an der Q&A-Session teilnehmen möchten, sollten einen separaten Link verwenden. Eine Wiederholung des Webcasts wird ungefähr zwei Stunden nach dem Abschluss des Anrufs auf der Investorenseite von Biodesix verfügbar sein. Teilnehmer werden empfohlen, 15 Minuten vor Beginn beizutreten.
- None.
- None.
Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time.
About Biodesix
Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit biodesix.com.
The Biodesix logo, Biodesix, Nodify Lung, Nodify XL2, Nodify CDT, IQLung, GeneStrat NGS, and VeriStrat are trademarks or registered trademarks of Biodesix, Inc. The ddPCR technology is a trademark of Bio-Rad Laboratories.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of backlog and the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital including under the term loan facility, expectations regarding revenue and margin growth and its impact on profitability, and the impact of a pandemic, epidemic, or outbreak, including the COVID-19 pandemic, on Biodesix and its operations and financial performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix most recent annual report on Form 10-K, filed March 1, 2024. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724005392/en/
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285
Investors:
Chris Brinzey
chris.brinzey@westwicke.com
(339) 970-2843
Source: Biodesix, Inc.
FAQ
When will Biodesix (BDSX) release its Q2 2024 financial results?
What time is Biodesix's (BDSX) Q2 2024 earnings call scheduled for?
How can investors access Biodesix's (BDSX) Q2 2024 earnings webcast?
What period does Biodesix's (BDSX) upcoming financial report cover?
